Literature DB >> 25900277

Erratum to: (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.

Ugo De Giorgi1, Paola Caroli, Emanuela Scarpi, Vincenza Conteduca, Salvatore Luca Burgio, Cecilia Menna, Andrea Moretti, Riccardo Galassi, Lorena Rossi, Dino Amadori, Giovanni Paganelli, Federica Matteucci.   

Abstract

Entities:  

Year:  2015        PMID： 25900277     DOI： 10.1007/s00259-015-3069-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  2 in total

1.  Prostate-specific antigen and radiolabelled choline PET/CT for the assessment of response to therapy: synergy or conflicting?

Authors:  Laura Evangelista; Emilio Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01       Impact factor: 9.236

2.  Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer.

Authors:  V Conteduca; E Scarpi; P Caroli; S Salvi; C Lolli; S L Burgio; C Menna; G Schepisi; S Testoni; G Gurioli; G Paganelli; V Casadio; F Matteucci; U De Giorgi
Journal:  Sci Rep       Date:  2017-11-14       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.